Diabetes Type 2

Ketogenic diet comes with cautions, new benefits of bempedoic acid, how to increase GDMT for type 2 diabetes, and CV consequences of cannabis lead findings from ACC 2023.

Each of the quotes is taken from a study reviewed on Patient Care during the week and was chosen for the research team’s passion about the clinical implications of their findings.

Your daily dose of clinical news you may have missed.

The SGLT-2 inhibitor, if approved for this age group, would be the first agent in the class with the indication as adjunctive treatment for T2D for those younger than age 18.

ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.

ACC 2023. Type 2 diabetes and CKD in patients with CVD are mutually independent predictors of MACE, concluded authors of a new study.

ACC 2023. New study found cognitive behavioral therapy delivered via mobile app significantly reduced HbA1c and need for antihyperglycemic intensification compared to use of a control app.

Foods that are "engineered" with refined carbohydrates and fats that are rapidly absorbed can lead to cravings on par with those for alcohol and nicotine, says Ashley Gearhardt, PhD.

Your daily dose of clinical news you may have missed.

The magnitude of the association with age did not change, however, for other stroke risk factors, including smoking, atrial fibrillation, and LVH, investigators report.

The beneficial effects of SGLT-2 inhibitors in reducing CV death and heart failure hospitalization in patients with T2D are related to body weight, suggest new data.

Your daily dose of clinical news you may have missed.

Risk of T2D was reduced by 49% over a 10-year follow up period among study participants who followed a vigorous or moderate exercise plan vs those who did not engage in exercise.

A pivotal study with 40-year follow-up of post-bariatric surgery patients reinforces long-term benefits of the procedures on all-cause and cause-specific mortality.

Your daily dose of clinical news you may have missed.

Bexagliflozin significantly improved glycemic control in adults when used as monotherapy, in combination with metformin, or when added to several SOC regimens.

Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.

Investigators report a 30% reduced risk of total joint replacement in persons with type 2 diabetes treated with metformin vs those who did not receive the drug.

The update removes a previous limitation that stated semaglutide should not be used as an initial therapy for treating patients with T2D.

Diabetes cases in the US among those younger than age 20 years, if left unchecked, are projected to increase by more than 600% by 2060, according to new projections.

A global prevalence of osteoporosis among persons with T2D of more than 25% calls for greater focus on screening for and managing the bone loss disease in this population.

Optimal glycemic control (less than 7%) in participants from the Look AHEAD trial was associated with smaller increases in frailty index score vs poorer control over the 8-year study period.

Find a compact sampling of 2022 research on type 2 diabetes and its treatment reviewed on Patient Care, chosen by the editorial staff.

Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.

About one-quarter of children with T2D are not obese, according to a meta-analysis, making comprehensive screening essential in the population.

The Dexcom G7 continuous glucose monitoring system provides an overall MARD of 8.2%, the highest of any FDA-cleared CGM, the company says.

Empagliflozin is the first SGLT-2 inhibitor to demonstrate a statistically significant reduction in HbA1c in children and adolescents with type 2 diabetes.

An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.